Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 16  |  Issue : 5  |  Page : 1007--1013

Effectiveness of radiofrequency ablation therapy for patients with unresected Stage IA non-small cell lung cancer


Ming Li1, Yingyi Qin2, Aihong Mei1, Changhui Wang1, Lihong Fan1 
1 Department of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China
2 Department of Health Statistics, Second Military Medical University, Shanghai 200433, China

Correspondence Address:
Changhui Wang
Department of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, #301 Mid Yanchang Rd., Shanghai 200072
China
Lihong Fan
Department of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072
China

Background: Approximately 20% of patients with resectable non-small cell lung cancer (NSCLC) are treated nonsurgically. To compare the clinical outcomes between nonsurgical patients receiving radiofrequency ablation (RFA) alone and those receiving no treatment (NT), we assessed RFA effectiveness in terms of survival using the surveillance, epidemiology, and end-results (SEER) database. Methods: Using the SEER registry process, we identified 5268 patients who were ineligible for the surgical treatment between 2004 and 2015. Overall survival (OS) and cancer-specific survival (CSS) were compared between the groups using propensity score matching (PSM), inverse probability of treatment weight (IPTW), and overlap weight analysis. In addition, an exploratory analysis was conducted to determine RFA treatment effectiveness based on clinically relevant patient subsets. Results: Of the 5268 patients, 189 (3.6%) received RFA. The OS and CSS in these patients were significantly better than those in the NT group (P < 0.0001). RFA was associated with a 16-month median OS improvement. Both OS and CSS improved in the nonsurgical patients (hazard ratio [HR], 0.695, 95% confidence interval [CI], 0.585–0.826, P < 0.0001; HR, 0.636; 95% CI, 0.505–0.800, P < 0.0001). The 1-, 3-, and 5-year OS in the unmatched RFA and NT groups were 84.2%, 49.0%, and 29.4% vs. 62.8%, 31.1%, and 17.1%, respectively (P < 0.001). PSM, IPTW, and overlap weight analysis showed comparable results. The odds of receiving RFA decreased with larger tumor size (>1, ≤2 cm, odds ratio [OR], 0.623, 95% CI, 0.402–0.966; >2, ≤3 cm, OR, 0.300, 95% CI, 0.186–0.483) compared to tumor size s1 cm (P < 0.05). Conclusion: RFA improves unresected stage IA NSCLC patient survival. Our results are limited by the retrospective nature of the study; however, we believe that our findings are noteworthy for recommending local ablative therapy.


How to cite this article:
Li M, Qin Y, Mei A, Wang C, Fan L. Effectiveness of radiofrequency ablation therapy for patients with unresected Stage IA non-small cell lung cancer.J Can Res Ther 2020;16:1007-1013


How to cite this URL:
Li M, Qin Y, Mei A, Wang C, Fan L. Effectiveness of radiofrequency ablation therapy for patients with unresected Stage IA non-small cell lung cancer. J Can Res Ther [serial online] 2020 [cited 2020 Dec 2 ];16:1007-1013
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2020;volume=16;issue=5;spage=1007;epage=1013;aulast=Li;type=0